The emergence of this tyrosine kinase for macrophage polarization supports the potential use of SFK-inhibitor such as dasatinib and imatinib, to reprogram the immunosuppressive macrophages to anti-tumour phenotype through blunting the HCK activity of TAMs. This evidence concerns the gene HCK and neoplasm.